Organon & Co. (NYSE:OGN – Get Free Report) announced a quarterly dividend on Tuesday, August 6th, Zacks reports. Shareholders of record on Friday, August 16th will be given a dividend of 0.28 per share on Thursday, September 12th. This represents a $1.12 dividend on an annualized basis and a yield of 5.75%. The ex-dividend date of this dividend is Friday, August 16th.
Organon & Co. has a dividend payout ratio of 24.3% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Organon & Co. to earn $4.31 per share next year, which means the company should continue to be able to cover its $1.12 annual dividend with an expected future payout ratio of 26.0%.
Organon & Co. Stock Performance
Organon & Co. stock traded up $0.84 during mid-day trading on Wednesday, reaching $19.49. 490,147 shares of the company were exchanged, compared to its average volume of 2,282,178. Organon & Co. has a twelve month low of $10.84 and a twelve month high of $24.08. The firm’s 50-day simple moving average is $20.82 and its two-hundred day simple moving average is $19.28. The company has a debt-to-equity ratio of 181.35, a quick ratio of 1.15 and a current ratio of 1.65. The firm has a market cap of $5.01 billion, a PE ratio of 4.56, a price-to-earnings-growth ratio of 1.01 and a beta of 0.85.
Analyst Upgrades and Downgrades
OGN has been the subject of several recent research reports. The Goldman Sachs Group raised their price target on Organon & Co. from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Piper Sandler boosted their price target on Organon & Co. from $22.00 to $24.00 and gave the stock an “overweight” rating in a research note on Monday, April 29th.
Read Our Latest Research Report on Organon & Co.
Organon & Co. Company Profile
Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.
Read More
- Five stocks we like better than Organon & Co.
- Which Wall Street Analysts are the Most Accurate?
- Nuclear Power Giant’s Shares Jump on Raised Full-Year Guidance
- Using the MarketBeat Stock Split Calculator
- Airbnb Stock: Key Drivers Indicate Bright Future Despite Sell-Off
- The How And Why of Investing in Oil Stocks
- Amgen’s MariTide Weight Loss Potential: Stock Outlook
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.